NIH Seeks CFS-XMRV patients for Study

January 31, 2011

Several teams of researchers at the National Institutes of Health

(NIH) have been studying XMRV and have been working to develop new and

more sensitive laboratory tests for it. One NIH team at the National

Cancer Institute, has recently received approval to obtain samples

directly from CFS patients. To be eligible for the study, you must

have a diagnosis of CFS and must be under the care of a physician. You

must also be willing and able to travel at your own expense to the NIH

campus in Bethesda, land for a screening evaluation.

The researchers are specifically trying to reach individuals who have

already been tested for XMRV so they can compare the results of their

new tests with the results obtained using other tests. People with

positive or negative results will be eligible to participate. The NIH

will share samples obtained in this study with other laboratories that

have tests for XMRV. The goal is to determine which kind of test is

best to detect XMRV. All participants will understand and give written

consent before any samples are obtained, tested or shared.

Participants have the right to withdraw from the study at any time.

Individuals who meet criteria for this study will make an appointment

to receive a physical examination, routine laboratory tests and

research tests at the NIH Clinical Center in Bethesda, land. This

study will not provide any medications. No new therapies, including

antiretroviral therapies, will be tested in this study.

If you are interested in participating, please contact Dr.

Maldarelli, the study contact, at his office directly at (301)

435-8019 for more information.

Participation in this study will not be coordinated through the

SolveCFS BioBank and any questions about it should be directed to the

NIH.

With best wishes for health and progress in the new year,

Gloria E.

SolveCFS BioBank Coordinator

The CFIDS Association of America

Our Mission:

For CFS to be widely understood, diagnosable, curable and preventable.

Our Strategy:

To stimulate research aimed at the early detection, objective

diagnosis and effective treatment of CFS through expanded public,

private and commercial investment.

Our Core Values:

To lead with integrity, innovation and purpose.

Recommended Posts